Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 22, 2005, Pages 5012-5015

  Cumming, John G ^a   Cooper, Anne E ^a   Grime, Ken ^a   Logan, Chris J ^a   McLaughlin, Sharon ^a   Oldfield, John ^a   Shaw, John S ^a   Tucker, Howard ^a   Winter, Jon ^a   Whittaker, David ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

CCR5; Chemokine receptor modulator

Indexed keywords

ACETANILIDE DERIVATIVE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5; PIPERIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; IC 50; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZENEACETAMIDES; BIOLOGICAL AVAILABILITY; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; MOLECULAR STRUCTURE; PIPERIDINES; RATS; RECEPTORS, CCR5; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 25844494409     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.08.014     Document Type: Article

References (16)

1. For a review of CCR5 as a target for HIV-1 and small molecule CCR5 ligands, see W. Kazmierski, N. Bifulco, H. Yang, L. Boone, F. DeAnda, C. Watson, and T. Kenakin Bioorg. Med. Chem. 11 2003 2663
2. N. Pipitone, and C. Pitzalis Curr. Opin. Anti-inflammat. Immunomodulat. Investig. Drugs 2 2000 9
3. M.P.M. Vierboom, P.J. Zavodny, C.-C. Chou, J.R. Tagat, C. Pugliese-Sivo, J. Strizki, R.W. Steensma, S.W. McCombie, L. Çelebi-Paul, E. Remarque, M. Jonker, S.K. Narula, and B. T'Hart Arthritis Rheum. 52 2005 627
4. F. Sellebjerg, H.O. Madsen, C.V. Jensen, J. Jensen, and P.J. Garred Neuroimmunology 102 2000 98
5. M. Fischereder, B. Luckow, R.P. Wüthrich, U. Rothenpieler, H. Schneeberger, U. Panzer, R.A.K. Stahl, I.A. Hauser, K. Budde, H.-H. Neumayer, B.K. Krämer, W. Land, and D. Schlöndorff Lancet 357 2001 1758
6. P.G. Andres, P.L. Beck, E. Mizoguchi, A. Mizoguchi, A.K. Bhan, T. Dawson, W.A. Kuziel, N. Maeda, R.P. MacDermott, D.K. Podolsky, and H.C. Reinecker J. Immunol. 164 2000 6303
7. J.N. Burrows, J.G. Cumming, S.M. Fillery, G.A. Hamlin, J.A. Hudson, R.J. Jackson, S. McLaughlin, and J.S. Shaw Bioorg. Med. Chem. Lett. 15 2005 25
8. Burrows, J.; Cooper, A.; Cumming, J.; McInally, T.; Tucker, H. WO 01/087839, 2001; Chem. Abstr. 2002, 135, 371644.
9. Cumming, J.; Tucker, H. WO 03/042177, 2003; Chem. Abstr. 2003, 138, 385312.
10. 125I]MIP- 1α, SPA beads (Amersham RPNQ0001) and membranes expressing the human CCR5 receptor. The signal was read on a Packard Topcount.
11. C. Hansch, A. Leo, S.H. Unger, K.H. Kim, D. Nikaitani, and E.J. Lien J. Med. Chem. 16 1973 1207
12. P.O. Seglan Methods Cell Biol. 13 1976 29
13. J.B. Houston, and D.J. Carlile Drug Metab. Rev. 29 1997 891
14. Compounds were also tested for stability to metabolism by human liver microsomes and in general the results reflected the stability in rat hepatocytes (data not shown).
15. For an example of this type of method, see W.A. Korfmacher, K.A. Cox, K.J. Ng, J. Veals, Y. Hsieh, S. Wainhaus, L. Broske, D. Prelusky, A. Nomeir, and R.E. White Rapid Commun. Mass Spectrom. 15 2001 335
16. H. Van de Waterbeemd, D.A. Smith, K. Beaumont, and D.K. Walter J. Med. Chem. 44 2001 1